EGFR and neoplasm: In situations of progression under EGFR-TKI, the better tumor sample to be used for molecular/histological analysis seems to be from the site of progression---tissue or cytological samples (i.e., pericarditis, pleural, and bronchoalveolar lavage)---if containing enough tumor cells.